St2 antigen binding proteins
US-2024368292-A1 · Nov 7, 2024 · US
Complete light chain, i.e. VL + CL
Complete light chain, i.e. VL + CL · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07K2317/515 |
| Official title | Complete light chain, i.e. VL + CL |
| Display label | Complete light chain, i.e. VL + CL |
| Total patents | 2,329 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is declining.
| Year | Patents |
|---|---|
| 2015 | 136 |
| 2016 | 248 |
| 2017 | 231 |
| 2018 | 223 |
| 2019 | 231 |
| 2020 | 257 |
| 2021 | 234 |
| 2022 | 216 |
| 2023 | 183 |
| 2024 | 174 |
| 2025 | 156 |
| 2026 | 40 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Monoclonal antibodies against claudin-18 for treatment of cancer
US-2024117022-A1 · Apr 11, 2024 · US
Antibodies against epidermal growth factor receptor (egfr) and uses thereof
US-2015368361-A1 · Dec 24, 2015 · US
Monoclonal antibodies against claudin-18 for treatment of cancer
US-9212228-B2 · Dec 15, 2015 · US
Production cell line enhancers
US-2015353634-A1 · Dec 10, 2015 · US
Method of making antibodies using a human lambda light chain mouse
US-9206263-B2 · Dec 8, 2015 · US
Anti-il-6 antibodies for the treatment of arthritis
US-2015344558-A1 · Dec 3, 2015 · US
Nucleic acids encoding antibodies that bind colony stimulating factor 1 receptor (CSF1R)
US-9200075-B2 · Dec 1, 2015 · US
VEGFR2/Ang2 Compounds
US-2015329626-A1 · Nov 19, 2015 · US
Therapeutic use of antibodies to hgf
US-2015322145-A1 · Nov 12, 2015 · US
Stable compositions of high-concentration allotype-selected antibodies for small-volume administration
US-9180205-B2 · Nov 10, 2015 · US
Common Light Chain Mouse
US-2015313193-A1 · Nov 5, 2015 · US
Production cell line enhancers
US-2015299310-A1 · Oct 22, 2015 · US
Production cell line enhancers
US-2015299309-A1 · Oct 22, 2015 · US
Hybrid light chain mice
US-9163092-B2 · Oct 20, 2015 · US
Methods and compositions for the treatment of proliferative and pathogenic diseases
US-9163086-B2 · Oct 20, 2015 · US
Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
US-2015290316-A1 · Oct 15, 2015 · US
Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
US-2015283264-A1 · Oct 8, 2015 · US
Human LCAT Antigen Binding Proteins and Their Use in Therapy
US-2015284471-A1 · Oct 8, 2015 · US
Hybrid light chain mice
US-9150662-B2 · Oct 6, 2015 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C07K2317/515?
- CPC C07K2317/515 is the Cooperative Patent Classification code for “Complete light chain, i.e. VL + CL.”
- How many patents are filed under CPC C07K2317/515 (Complete light chain, i.e. VL + CL)?
- Our database includes 2,329 publications tagged with this CPC code.
- Is patent activity under CPC C07K2317/515 growing?
- Publication counts under this code: 174 in 2024 vs 156 in 2025 (latest complete years).